Navigation Links
Derma Sciences Announces Date of Its First Quarter 2008 Earnings Release and Conference Call on May 15, 2008
Date:5/7/2008

PRINCETON, N.J., May 7 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bullentin Board: DSCI), provider of advanced wound care products, announced plans to release its first quarter 2008 results before market on Thursday, May 15, 2008. The Company will hold a conference call that same day to discuss the results at 11:00 am EDT. Interested parties should call 866 202 4683 (domestic) or 617 213 8846 (international), with passcode 26916332 to access the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=1830398

For those who are unavailable to listen to the live broadcast, a replay will be available through June 15, 2008 and can be accessed by dialing 888 286 8010 (domestic) and 617 801 6888 (international) and using passcode is 80070508.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand - the licensor of the patented honey- based technology - and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in variety of wounds and burns, and was recently the focus of a large scale randomized controlled trial on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com .

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermascie
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. QUANTEL Intends to Strengthen its Dermatology/ Aesthetics Division With the Acquisition of WaveLight Aesthetic GmbH
2. Dermatologists identify North Texas leishmaniasis outbreak
3. Tissue-Growth Gene Tied to Scleroderma
4. American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification (TAN) Act
5. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
6. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
7. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
8. American Academy of Dermatology: New Study Finds Women More Likely Than Men to be Affected by Acne as Adults
9. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
10. Dermatologists Warn Fitness Enthusiasts: Dont Let Exercise-Related Skin Problems Outweigh the Benefits of Physical Activity
11. Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ies support providers in discussing health care co...As health care costs continue to rise, many employ...o their employees through higher premiums or cost-... and coinsurance. To help consumers better underst...viders, such as primary care physicians, specialis...
(Date:12/1/2008)...Medicare Prescription Drug Enrollment Period Is Ha... WASHINGTON, Dec. 1 The...nt period is nearly halfway over - running from No...nt period is an opportunity for seniors to change ... currently enrolled or for those not enrolled in a...
(Date:12/1/2008)...Dec. 1 Sciton introduces ProLipo,...a high-powered laser system,for ablating and melt... and,tissue tightening. ProLipo PLUS combines 10...timal body sculpting results. Frequently used as ...o be utilized as a standalone procedure,for patie...
(Date:12/1/2008)...R HONORED FOR CAREER OF SCIENTIFIC DISCOVERY IN MO... The Radiologic Society of North Am...th its "Outstanding Researcher of The Year" Award,...o has made original significant contributions to t...rch. Dr. Weissleder is Professor at Harvard Medic...
Breaking Medicine News(10 mins):Health News:Don't Know How Much an X-Ray Costs You? Highmark Network Providers Will Begin Having Conversations With Highmark Members About Their Actual Cost of Care 2Health News:Don't Know How Much an X-Ray Costs You? Highmark Network Providers Will Begin Having Conversations With Highmark Members About Their Actual Cost of Care 3Health News:Don't Know How Much an X-Ray Costs You? Highmark Network Providers Will Begin Having Conversations With Highmark Members About Their Actual Cost of Care 4Health News:Radio Interview Opportunity: Important News for Seniors 2Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3
...ccessful cloning has been a dream come true for th...he U.S. Food and Drug Administration is expected t...unce soon that milk // from cloned animals, as wel... Canada holds the credit when it comes to cloning...
...u may expect your partner to inform you of his/her...e a legal stand on this. Even horrifying is the fa...to protect you // from the virus. The Wellington D...the charges of criminal nuisance against Justin Da...
...botic surgery could finally prove to be an answer ...the disease. Surgical treatment of prostate cancer...pain, scarring and a // reduction in the post-oper...s the second leading cause of death among American...
...rdasil is the new cervical vaccine developed by Sa... in its phase III trial, the vaccine is given in t...essful. The company is // to apply for a license t...lloma virus infection and also genital warts, whic...
Other Medicine News:Health News:Ruling On Non Disclosure Of HIV Positive Status Is Not Ethical 2Health News:Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer 2Health News:Gardasil vaccine for cervical cancer 2
(Date:11/25/2008).... 25 Proteolix, Inc., a,leader in...cs that target,protein degradation pathways in ca...t data from two ongoing Phase 2 clinical trials of...d at the upcoming 50th Annual Meeting of the,Amer...the first in a new class,of specific proteasome i...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
(Date:11/24/2008)...swire/ -- Domino,s Pizza (NYSE: DPZ ), the,reco...up to raise dough for,the kids of St. Jude Childr...anks and Giving campaign. Domino,s customers will ...of purchase to benefit the children of St. Jude.,... or when ordering online at, www.dominos.com . Th...
(Date:11/24/2008)... leadership and long-term commitment to hepatitis ...ewswire-FirstCall/ -- Schering-Plough Corporation ... boceprevir, its lead investigational oral hepatit...elopment. The company believes boceprevir has the...s protease inhibitor for treating chronic hepatiti...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year End 2007 Financial Results 11912 1Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year End 2007 Financial Results 11912 2Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year End 2007 Financial Results 11912 3Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year End 2007 Financial Results 11912 4GSK Launches New Website to Help Employers Lower Costs and Improve the Health of Workers 11910 1GSK Launches New Website to Help Employers Lower Costs and Improve the Health of Workers 11910 2GSK Launches New Website to Help Employers Lower Costs and Improve the Health of Workers 11910 3GSK Launches New Website to Help Employers Lower Costs and Improve the Health of Workers 11910 4Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 3307 1Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 3307 2Acute Coronary Events Drop After Italys Public Smoking Ban 11909 1Acute Coronary Events Drop After Italys Public Smoking Ban 11909 2
...., April 17, 2007,/PRNewswire-FirstCall/ -- Cell G...rom two previously conducted Phase 2 clinical tria...uation of antibody,responses in patients with adva... the GVAX cell-based immunotherapy induces,antibod...ssociated,antigens, including some not previously ...
...-Apr 17, 2007 - A 9-month, randomized,double-blin...mparing a 40 mg dose of COPAXONE(R) given daily to...wed a 38 percent greater,reduction in inflammatory...e images (MRI) of the brain. In addition, patients...an on-trial relapse rate,of 77 percent when compar...
Other Medicine Technology:Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 2Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 3Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: